Table 2.
Overview of clinical trials of cryoablation, radiofrequency ablation(RFA) and microwave ablation (MWA) combined with immunotherapy.
| Global NCT Number | Phase | Ablation type | Combination immunotherapy intervention | Type of Malignancy | Outcome Measures | References(PMID) |
|---|---|---|---|---|---|---|
| NCT03949153 | Phase 1 Phase 2 |
Cryoablation | Nivolumab; Ipilimumab. |
Melanoma (Skin) | Number of failures linked to the procedure. | |
| NCT01065441 | Phase 1 Phase 2 |
Cryoablation | AlloStim | Solid Tumors Stage II, Stage III and Stage IV; Breast Cancer; Colorectal Cancer; Prostate Cancer; Melanoma; Ovarian Cancer; Sarcoma; Non-small Cell Lung Cancer. |
The primary endpoint is the evaluation of any drug-related toxicity associated with AlloStimTM administration as well as the reversibility of such toxicity. | 18834631; 18565579; 18054441. |
| NCT02380443 | Phase 2 | Cryoablation | AlloStim | Colorectal Cancer Metastatic | To determine the safety of increased frequency of dosing | 23786302; 23734882; 22075702; 21123824; 18834631; 18565579; 18054441; 24777185. |
| NCT03546686 | Phase 2 | Cryoablation | Ipilimumab; Nivolumab. |
Breast Cancer | Event-Free Survival | |
| NCT04339218 | Phase 3 | Cryoablation | Pembrolizumab | Lung Adenocarcinoma | 1-year overall survival rate | |
| NCT01853618 | Phase 1 Phase 2 |
Radiofrequency Ablation; Cryoablation |
Tremelimumab | Heptocellular Cancer; Biliary Tract Neoplasms; Liver Cancer; Hepatocellular Carcinoma; Biliary Cancer. |
Number of Participants with Serious and Non-Serious Adverse Events Regardless of Attribution | 30578687; 30688989; 27816492; 28923358. |
| NCT03695835 | Radiofrequency Ablation; Cryotherapy | Yervoy; Keytruda; Leukine. |
Adenocarcinoma | MyVaccx immunotherapy treatment impact on late stage cancer disease | ||
| NCT04707547 | Phase 4 | Radiofrequency Ablation | Nivolumab | Liver Cancer | Analysis of the number of CD8+ T | |
| NCT03067493 | Phase 2 | Radiofrequency ablation | Neo-MASCT | Primary Liver Cancer; Hepatectomy |
Disease free survival | 23269991; 16087270; 26933175; 14559842; 22353262. |
| NCT03101475 | Phase 2 | Radiofrequency ablation | Durvalumab; Tremelimumab |
Colorectal Cancer Liver Metastases |
Best overall immune response rate (iBOR) of lesions not treated by ablation/radiotherapy including the extrahepatic lesions according to iRECIST (with response confirmation) | |
| NCT03753659 | Phase 2 | Radiofrequency ablation; Microwave Ablation | Pembrolizumab | Hepatocellular Carcinoma | Objective response rate (ORR) according to RECIST 1.1 | |
| NCT03864211 | Phase 1 Phase 2 |
Radiofrequency ablation; microwave ablation | Toripalimab | Hepatocellular Carcinoma Non-resectable | Progression free survival | 24714771; 29872177; 30805896; 30191038; 24561446; |
| NCT03939975 | Phase 2 | Radiofrequency Ablation; Microwave Ablation | Pembrolizumab; nivolumab; JS001. | Hepatocellular Carcinoma | Adverse events | 33163408. |
| NCT04220944 | Phase 1 | Microwave Ablation | Sintilimab | Hepatic Carcinoma | Progression Free Survival | |
| NCT04805736 | Phase 2 | Microwave Ablation | Camrelizumab | Breast Cancer | Safety of Microwave Ablation Combined with Camrelizumab | |
| NCT04156087 | Phase 2 | Microwave Ablation | Durvalumab; Tremelimumab. |
Pancreatic Cancer Non-resectable | Progression-free survival | |
| NCT04888806 | Phase 2 | Microwave Ablation | Camrelizumab | Colorectal Cancer Metastatic; Liver Metastases; Lung Metastases. |
12-month progression-free survival | |
| NCT02851784 | Phase 2 Phase 3 |
Microwave Ablation | adoptive immunotherapy | Hepatocellular Carcinoma | Cumulative survival rates were calculated by the Kaplan-Meier method, and comparison between Microwave Ablation and combination treatment will be done by the log-rank test |